Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.37 ^USD	+3.49%		+6.88%	-42.14%

Mar. 12	Transcript : Relay Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
Feb. 23	Relay Therapeutics Q4 Loss Widens, Reports No Revenue	MT

Relay Therapeutics, Inc. announced that it has received $30 million in funding

January 09, 2024

On January 10, 2024, Relay Therapeutics, Inc. closed the transaction. The company will issue securities pursuant to exemption provided under Regulation D. The transaction included participation from a single investor.

Latest news about Relay Therapeutics, Inc.

Transcript : Relay Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	Mar. 12
Relay Therapeutics Q4 Loss Widens, Reports No Revenue	Feb. 23	MT
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Relay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Relay Therapeutics, Inc. announced that it has received $30 million in funding	Jan. 09	CI
Transcript : Relay Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02:15 PM	Jan. 09
Relay Therapeutics to Raise $30 Million From Private Placement	Jan. 08	MT
Relay Therapeutics, Inc. announced that it expects to receive $30 million in funding	Jan. 07	CI
HC Wainwright Adjusts Price Target on Relay Therapeutics to $17 From $19, Keeps Buy Rating	Dec. 11	MT
HC Wainwright Lowers Price Target on Relay Therapeutics to $19 From $33, Maintains Buy Rating	Nov. 08	MT
Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q3 Revenue $25.2M	Nov. 02	MT
Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Transcript : Relay Therapeutics, Inc. - Special Call	23-10-12
Relay Therapeutics' Cancer Medicine Benefits Patients, Initial Data Shows; Shares Jump	23-10-12	MT
Relay Therapeutics, Inc. Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors	23-10-12	CI
HC Wainwright Adjusts Price Target on Relay Therapeutics to $30 From $32, Keeps Buy Rating	23-08-17	MT
Relay Therapeutics' Q2 Loss Widens	23-08-09	MT
Relay Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Earnings Flash (RLAY) RELAY THERAPEUTICS Reports Q2 Revenue $119,000	23-08-08	MT
Relay Therapeutics, Inc.(NasdaqGM:RLAY) dropped from Russell 3000E Growth Index	23-06-23	CI
Relay Therapeutics, Inc.(NasdaqGM:RLAY) dropped from Russell 3000 Growth Index	23-06-23	CI
Relay Therapeutics, Inc.(NasdaqGM:RLAY) dropped from Russell 2500 Growth Index	23-06-23	CI
Relay Therapeutics, Inc.(NasdaqGM:RLAY) dropped from Russell Small Cap Comp Growth Index	23-06-23	CI
Relay Therapeutics, Inc.(NasdaqGM:RLAY) dropped from Russell 2000 Growth Index	23-06-23	CI
Transcript : Relay Therapeutics, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-13-2023 10:00 AM	23-06-13

Chart Relay Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Companyâs Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Companyâs lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3KÎ±), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Relay Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.37 USD

Average target price

23.05 USD

Spread / Average Target

+261.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RELAY THERAPEUTICS, INC.	-42.14%	843M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research